Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of BW-40202 in paroxysmal nocturnal hemoglobinuria
CTR20261241Phase 2Active
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BW-40202 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd.. Started Apr 2026; status: active.
02
Drugs
BW-40202
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20261241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261241.